Login / Signup

Fecal Microbiota Transplantation in Reducing Uremic Toxins Accumulation in Kidney Disease: Current Understanding and Future Perspectives.

Gianvito CaggianoAlessandra StasiRossana FranzinMarco FiorentinoMaria Teresa CimmarustiAnnamaria DeleonardisRita PalieriPaola PontrelliLoreto Gesualdo
Published in: Toxins (2023)
During the past decades, the gut microbiome emerged as a key player in kidney disease. Dysbiosis-related uremic toxins together with pro-inflammatory mediators are the main factors in a deteriorating kidney function. The toxicity of uremic compounds has been well-documented in a plethora of pathophysiological mechanisms in kidney disease, such as cardiovascular injury (CVI), metabolic dysfunction, and inflammation. Accumulating data on the detrimental effect of uremic solutes in kidney disease supported the development of many strategies to restore eubiosis. Fecal microbiota transplantation (FMT) spread as an encouraging treatment for different dysbiosis-associated disorders. In this scenario, flourishing studies indicate that fecal transplantation could represent a novel treatment to reduce the uremic toxins accumulation. Here, we present the state-of-the-art concerning the application of FMT on kidney disease to restore eubiosis and reverse the retention of uremic toxins.
Keyphrases
  • oxidative stress
  • cell therapy
  • stem cells
  • big data
  • combination therapy
  • mesenchymal stem cells
  • artificial intelligence
  • deep learning
  • case control